Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

HRT and breast cancer risk: a realistic perspective.

Stevenson JC, Hodis HN, Pickar JH, Lobo RA.

Climacteric. 2011 Dec;14(6):633-6. doi: 10.3109/13697137.2011.590618. Epub 2011 Aug 24.

PMID:
21864135
4.
5.

Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.

de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F.

Climacteric. 2002 Dec;5(4):332-40.

PMID:
12626212
6.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
7.

Hormone replacement therapy in postmenopausal women.

Yasui T, Uemura H, Takikawa M, Irahara M.

J Med Invest. 2003 Aug;50(3-4):136-45. Review.

PMID:
13678382
8.

Perspectives on the Women's Health Initiative trial of hormone replacement therapy.

Grimes DA, Lobo RA.

Obstet Gynecol. 2002 Dec;100(6):1344-53. Review.

PMID:
12468183
9.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669
10.

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E.

Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9.

PMID:
10068383
11.

The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.

Hillman JJ, Zuckerman IH, Lee E.

J Womens Health (Larchmt). 2004 Nov;13(9):986-92.

PMID:
15665655
12.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT.

Maturitas. 2005 Sep 16;52(1):1-10. Review.

13.

Postmenopausal hormone therapy: have HERS2 and WHI given us any new information?

Fylstra DL.

J S C Med Assoc. 2002 Dec;98(8):299-304.

PMID:
12532655
14.

Breast cancer risk in the WHI study: the problem of obesity.

Kuhl H.

Maturitas. 2005 May 16;51(1):83-97. Review.

PMID:
15883113
15.

Recent concerns surrounding HRT.

Armitage M, Nooney J, Evans S.

Clin Endocrinol (Oxf). 2003 Aug;59(2):145-55. Review.

PMID:
12864790
16.
17.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
18.

Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial.

Ness J, Aronow WS, Newkirk E, McDanel D.

J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):460-2.

PMID:
15933383
19.

Effect of endogenous and exogenous hormones on breast cancer: epidemiology.

Vessey MP.

Verh Dtsch Ges Pathol. 1997;81:493-501. Review.

PMID:
9474890
20.

Breast cancer and HRT--what are the data?

Bieber EJ, Barnes RB.

Int J Fertil Womens Med. 2001 Mar-Apr;46(2):73-8. Review.

PMID:
11374658

Supplemental Content

Support Center